{
    "ticker": "IMRX",
    "name": "Immuneering Corporation",
    "description": "Immuneering Corporation is a biotechnology company focused on developing innovative therapies for patients with cancer and other serious diseases. Founded in 2018, Immuneering leverages its proprietary platform to identify and develop small molecule drugs that target critical pathways in tumor biology. The company\u2019s approach combines deep biological insights with advanced computational methods to create a unique drug discovery process. Immuneering's lead candidate, IMM-1-104, is currently in clinical development for treating solid tumors, representing a novel approach to overcoming resistance to existing therapies. With a robust pipeline that includes several additional candidates in various stages of development, Immuneering aims to address significant unmet medical needs in oncology. The company is dedicated to advancing the science of precision medicine, with a focus on optimizing treatment for individual patients based on their unique tumor profiles. Immuneering's commitment to innovation and collaboration with leading research institutions and clinical experts positions it as a promising player in the biotechnology landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2018",
    "website": "https://www.immuneering.com",
    "ceo": "Ben Hwang",
    "social_media": {
        "twitter": "https://twitter.com/Immuneering",
        "linkedin": "https://www.linkedin.com/company/immuneering/"
    },
    "investor_relations": "https://investors.immuneering.com",
    "key_executives": [
        {
            "name": "Ben Hwang",
            "position": "CEO"
        },
        {
            "name": "Mark L. H. G. C. DeVito",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Candidates",
            "products": [
                "IMM-1-104"
            ]
        }
    ],
    "seo": {
        "meta_title": "Immuneering Corporation | Innovative Biotech Solutions for Cancer",
        "meta_description": "Explore Immuneering Corporation, a biotechnology company focused on developing precision therapies for cancer. Learn about our innovative drug candidates and commitment to patient-centric solutions.",
        "keywords": [
            "Immuneering",
            "Biotechnology",
            "Cancer Therapy",
            "Precision Medicine",
            "IMM-1-104"
        ]
    },
    "faq": [
        {
            "question": "What is Immuneering known for?",
            "answer": "Immuneering is known for developing innovative therapies for cancer using its proprietary drug discovery platform."
        },
        {
            "question": "Who is the CEO of Immuneering?",
            "answer": "Ben Hwang is the CEO of Immuneering Corporation."
        },
        {
            "question": "Where is Immuneering headquartered?",
            "answer": "Immuneering is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Immuneering's main products?",
            "answer": "Immuneering's main product is the drug candidate IMM-1-104, aimed at treating solid tumors."
        },
        {
            "question": "When was Immuneering founded?",
            "answer": "Immuneering was founded in 2018."
        }
    ],
    "competitors": [
        "NKLA",
        "CLVS",
        "EDIT",
        "ZIOP"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "GILD",
        "NVS"
    ]
}